Bio News
As of 2025, approximately 30% of the world’s innovative drug assets originated in China, but more than 52% of these assets were licensed out at an early stage before Phase 1 clinical trials. This indicates that China has secured the ability to discover drug candidates but lacks the global clinical development capabilities needed to precisely validate efficacy in small patient populations. In fact, the success rate for oncology drugs from Phase 1 through FDA approval is less than 5%, suggesting that future success or failure will depend on clinical development capabilities.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
